Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 2017
Event: Entry into a Material Definitive Agreement (Stock Purchase Agreement) with KBI Biopharma, Inc.
Key Financial Metrics
This filing details a specific capital transaction rather than periodic financial performance. Key figures include:
- Gross Proceeds: Approximately $6.8 million raised via private placement.
- Shares Issued: 776,104 shares of common stock.
- Issuance Price: $8.77 per share (based on 10-day VWAP ending Nov 30, 2017).
- Debt/Expense Waiver: The transaction waived a $4.1 million postponement fee and a $2.7 million campaign reservation fee owed to KBI.
- Contingent Liability: Potential cash royalty payments to KBI not to exceed $0.7 million, contingent on delivery timing of 27 batches of CHS-1701.
Note: The filing text does not provide clear values for overall revenue, net profit, operating cash flow, margins, or total debt levels for the company.
Material Changes
The primary material change is the conversion of specific manufacturing fees into equity and contingent value rights:
- Fee Elimination: The Company avoided immediate cash outflows for a $4.1 million postponement fee (related to the 2017 CHS-1701 campaign) and a $2.7 million reservation fee (for the second 2018 campaign).
- Capital Structure: Issuance of new shares to KBI Biopharma, Inc., a contract manufacturing organization and existing partner.
- Batch Fees: Certain batch fees were increased until the 2018 manufacturing campaign begins, offset by the equity issuance.
Guidance, Outlook, and Risks
- Management Commentary: The transaction was structured to secure manufacturing capacity for the CHS-1701 (pegfilgrastim biosimilar) campaign while raising capital and deferring cash payments.
- Registration Rights: The Company agreed to file a registration statement for the resale of shares within 60 days of the agreement (by Jan 29, 2018) and use commercially reasonable efforts to have it declared effective within 100 days of filing.
- Risks/Contingencies: Future cash outflows are contingent on KBI's delivery schedule for 27 batches of CHS-1701. Failure to meet delivery timelines could trigger the $0.7 million royalty cap.
- Unusual Items: The transaction is exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Investor Verification Checklist
- Verify the closing date of the private placement (December 1, 2017) and the actual number of shares issued.
- Confirm the specific terms of the Contingent Value Rights Agreement regarding the $0.7 million royalty cap and delivery milestones.
- Review the impact of the waived fees ($6.8 million total) on the Company's cash flow projections for 2017 and 2018.
- Monitor the status of the shelf registration statement filing required within 60 days of the agreement.
- Assess the dilution impact of the 776,104 new shares on existing shareholders.